Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V:
EVE; OTCQX: EEVVF) is pleased to announce that its wholly-owned
subsidiary, Natural MedCo Ltd. (“NMC”), entered into a licensing
agreement with Dr. Kerklaan Therapeutics (the “Agreement”) on
December 7, 2020.
The Agreement contemplates the exclusive right
and license to manufacture, promote, distribute and sell the
following products in Canada under the Dr. Kerklaan Therapeutics
brand, under the Eve & Co brand, or as co-branded products
under the Eve & Co and Dr. Kerklaan Therapeutics brands:
Natural CBD Relief Cream, Natural CBD Relief Stick, Natural CBD
Spray, Natural CBD Sleep Cream, Natural CBD Skin Cream, Natural CBD
PMS Cream.
The Agreement also contemplates product
development and marketing collaborations between Eve & Co and
Dr. Kerklaan Therapeutics and potential expansion beyond existing
markets for the Dr. Kerklaan Therapeutics brand presence in the
United States, United Kingdom and, together with Eve & Co,
Canada.
The term of the Agreement is for an initial
five-year period, which commenced on December 7, 2020, with a
further five-year option in favour of NMC and stipulates licensing
royalties. The Company anticipates manufacturing and distributing
cannabis-infused topicals to the Canadian market in the first
quarter of 2021.
“We are delighted to partner with such a
well-established and respected brand. Dr. Kerklaan Therapeutics has
developed a collection of effective cannabis topical products
backed by a dedicated team ensuring quality and support,” said
Melinda Rombouts, President & CEO of Eve & Co. “The
introduction of Dr. Kerklaan Therapeutics’ topical cannabis creams
into Canada serves as an important milestone for both of our
companies, and we look forward to expanding into a meaningful
consumer segment.”
The addition of the Dr. Kerklaan Therapeutics
line of cannabis-infused topicals complements Eve & Co’s roster
of 2.0 cannabis products. The Company previously announced that it
had partnered with Colio Estate Wines to create a premium
cannabis-infused beverage inspired by the Girls’ Night Out wine
label.
“Launching into Canada is an important milestone
for the Dr. Kerklaan Therapeutics brand. The strategic partnership
with Eve & Co. allows us to expand our international reach to
Canadian health and wellness consumers with our premium cannabis
and CBD-focused products,” said founder, Dr. Andrew Kerklaan. “As a
Canadian, I am proud to see our products launch at
home.”
Dr. Kerklaan Therapeutics’ products have been
featured in Vogue, The Oprah Magazine, Forbes, Allure, Goop,
Esquire and Rolling Stone magazines as well as other publications
as a leading hemp-based CBD skincare product.
ABOUT EVE & CO
INCORPORATED
Eve & Co, through its wholly-owned
subsidiary NMC, holds cultivation and processing licences under the
Cannabis Act (Canada) for the production and sale of various
cannabis products, including dried cannabis, cannabis plants and
extracts and has received its European Union certificate of Good
Manufacturing Practice which allows Eve & Co to distribute its
products to the European Union. NMC was Canada’s first
female-founded licensed producer of medicinal marijuana and
received its cultivation licence from Health Canada in 2016. Eve
& Co is led by a team of agricultural experts and has a
licensed 1,000,000 square foot greenhouse located in Strathroy,
Ontario.
The Company’s website can be visited at
www.evecannabis.ca.
ABOUT DR. KERKLAAN
THERAPEUTICS
Dr. Kerklaan Therapeutics provides upscale,
highly effective plant-based CBD topical solutions. Dr. Kerklaan
Therapeutics' approach to designing CBD-infused health and wellness
products blends modern biochemistry with time-tested
cannabidiol-based remedies. Made with the highest quality
ingredients, Dr. Kerklaan Therapeutics combines premium essential
oils with cannabis and CBD hemp extracts. All of Dr. Kerklaan
Therapeutics’ products are rigorously tested by independent
third-party labs for quality and cannabinoid concentration
certification and are made to the highest standards of safety and
efficacy. Dr. Kerklaan Therapeutics’ products are distributed
throughout the USA, UK and Europe.
Learn more at www.DrKerklaan.com
Neither the TSX Venture Exchange nor its
regulation services provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Notice regarding forward looking
statements:
Certain statements in this press release
constitute forward-looking information. All statements other than
statements of historical fact contained in this press release,
including, without limitation, those regarding the approval of new
products, the successful production and launch of the Company’s new
cannabis derivative products and timing thereof, consumer
preferences, competition, opportunities for growth, future,
strategy, plans, objectives, goals and targets, and any statements
preceded by, followed by or that include the words “believe”,
“expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”,
“would”, “anticipate”, “estimate”, “forecast”, “predict”,
“project”, “seek”, “should” or similar expressions or the negative
thereof, are forward-looking statements. These statements are not
historical facts but instead represent only the Company’s
expectations, estimates and projections regarding future events.
These statements are not guarantees of future performance and
involve assumptions, risks and uncertainties that are difficult to
predict, including those described in the Company’s management’s
discussion and analysis for the three and nine months ended
September 30, 2020 which is available on the Company’s SEDAR
profile. Therefore, actual results may differ materially from what
is expressed, implied or forecasted in such forward-looking
statements. The forward-looking information and forward-looking
statements included in this news release are made as of the date of
this news release. The Company does not undertake an obligation to
publicly update such forward-looking information or forward-looking
information to reflect new information, subsequent events or
otherwise unless required by applicable securities law.
For further information, please contact:
Melinda RomboutsPresident and Chief Executive OfficerEve &
Co IncorporatedTelephone: (855)
628-6337
Jennifer MillerCommunicationsDr. Kerklaan TherapeuticsTelephone:
(514) 476-1178
Eve & (TSXV:EVE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eve & (TSXV:EVE)
Historical Stock Chart
From Jul 2023 to Jul 2024